Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $7.00 target price on the stock.
Separately, Benchmark reiterated a “buy” rating and set a $5.00 price objective on shares of Clene in a research report on Thursday, May 23rd.
Check Out Our Latest Report on Clene
Clene Trading Up 1.7 %
Clene (NASDAQ:CLNN – Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Clene had a negative net margin of 7,873.23% and a negative return on equity of 224.28%. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.16 million. Sell-side analysts forecast that Clene will post -0.34 earnings per share for the current year.
Clene Company Profile
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Featured Articles
- Five stocks we like better than Clene
- Consumer Discretionary Stocks Explained
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- 3 Small Caps With Big Return Potential
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- How to Read Stock Charts for Beginners
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.